lifestyle.buyersdesire.org

Author: Jaguar Health, Inc.

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health’s Special One-time Stock Dividend

March 12, 2026
Jaguar Health Announces a Special One-time Stock Dividend

March 11, 2026
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

January 25, 2026
Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

January 18, 2026
Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

January 12, 2026
Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

January 8, 2026
Article About Groundbreaking Results from Study of Jaguar Health’s Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

January 6, 2026
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

December 15, 2025
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

December 10, 2025
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

December 8, 2025